STATE OF WISCONSIN
Controlled Substances Board
IN THE MATTER OF RULE-MAKING PROCEEDINGS BEFORE THE
CONTROLLED SUBSTANCES BOARD
ORDER OF THE CONTROLLED SUBSTANCES BOARD
ADOPTING RULES
(CLEARINGHOUSE RULE 15-007)
ORDER
An order of the Controlled Substances Board to create CSB 2.37 relating to rescheduling hydrocodone combination products.
Analysis prepared by the Department of Safety and Professional Services.
---------------------------------------------------------------------------------------------------------------------
ANALYSIS
Statutes interpreted: s. 961.18, Stats. Explanation of agency authority:
961.11(4) If a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of
issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30−day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2). Related statute or rule: N/A
Plain language analysis:
The Controlled Substances Board did not receive an objection to treating hydrocodone combination products as a schedule II instead of schedule III under ch. 961, Stats. based upon the federal scheduling. The Controlled Substances Board took affirmative action on October 7, 2014 to similarly treat hydrocodone combination products under chapter 961 effective November 1, 2014 to allow for publication in the Administrative Register. The Affirmative Action Order will expire upon promulgation of a final rule. This rule repeals sections 961.18(5)(c) and (d) which reschedules hydrocodone combination products from a schedule III to a schedule II.
Summary of, and comparison with, existing or proposed federal regulation:
On August 22, 2014, the United States Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register rescheduling hydrocodone combination products from a schedule III to a schedule II of the federal Controlled Substances Act. The scheduling action was effective October 6, 2014.
Comparison with rules in adjacent states:
Illinois: Illinois has not rescheduled hydrocodone combination products.
Iowa: Iowa is in the process of promulgating an administrative rule to amend the Iowa statutes to reschedule hydrocodone combination products from schedule III to schedule II.
Michigan: Michigan has not rescheduled hydrocodone combination products.
Minnesota: Minnesota has not rescheduled hydrocodone combination products.
Summary of factual data and analytical methodologies:
The methodology was to reschedule hydrocodone combination products to conform with the federal Controlled Substances Act.
Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:
None.
Fiscal Estimate and Economic Impact Analysis:
